Google Enhances Enterprise Chrome With AI Automation And Advanced Security

by THEFUTURE.TEAM

April 23, 2026

Google Cloud Next Unveils Chrome AI Updates For Enterprise

At Google Cloud Next, Google announced updates to its Chrome browser focused on AI-driven automation and enterprise security. The changes introduce new capabilities powered by Gemini and expand controls for IT teams managing enterprise environments.

Auto Browse: Redefining Productivity

The new “auto browse” feature uses Gemini to interpret activity across open tabs and assist with task execution. Use cases include booking travel, scheduling meetings, and entering data into systems such as CRM platforms. The goal is to reduce time spent on repetitive workflows and support more efficient task handling within enterprise settings.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Human Oversight Remains Paramount

Google said users will remain responsible for reviewing and confirming AI-generated actions. This “human-in-the-loop” approach is designed to limit errors and maintain control over automated processes, particularly in environments where accuracy is critical.

Expanding Security And Visibility

Alongside productivity features, Google is extending security capabilities within Chrome Enterprise. New tools aim to detect unsanctioned AI usage and unusual agent activity. These controls provide IT teams with greater visibility into both approved and unauthorized applications, supporting risk management and compliance.

Collaborations And Integration With Leading Security Providers

Google also announced expanded integration with Okta to address risks such as session hijacking. Additional support for Microsoft Information Protection allows organizations to apply consistent data security policies across Chrome and connected services.

Strategic Shift In Enterprise AI Adoption

The update reflects a broader move to embed AI into widely used workplace tools. While automation may improve efficiency, its impact on overall workloads remains mixed, with some studies suggesting increased task complexity alongside productivity gains. Initial availability is limited to Workspace users in the United States, with further rollout expected as enterprise adoption evolves.

The Future Forbes Realty Global Properties

Colossal Biosciences Seeks Funding At Up To $30 Billion Valuation

by THEFUTURE.TEAM

July 22, 2026

Colossal Biosciences, the biotechnology startup known for its efforts to revive extinct species including the woolly mammoth and dire wolf, is in talks to raise funding at a valuation of $20 billion to $30 billion, according to Axios.

The company was last valued at $10.2 billion in a January funding round. It has since begun generating revenue, Axios reported, although neither the size of the new financing nor its potential investors have been disclosed.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Business Extends Beyond De-Extinction

While Colossal has attracted global attention for its de-extinction projects, the company is also building a broader biotechnology business around the tools developed through that research.

Co-founder and Chief Executive Ben Lamm has said Colossal expects revenue from three areas: conservation technologies, new businesses created from its research and future commercial applications of technologies developed alongside its de-extinction programme.

Expanding Commercial Portfolio

Colossal has already supplied conservation technology to the U.S. government and the United Arab Emirates, which recently invested $60 million in the company, according to Wired.

Its research has also led to the creation of several startups, including plastics recycling company Breaking, computational biology platform Form Bio, which raised $30 million, and AI-driven biology company Astromech, which was valued at $2 billion in March.

Research Continues To Expand

Operating from a 55,000-square-foot facility in Dallas, Colossal continues to broaden its research portfolio.

In April, the company added the bluebuck antelope as its sixth de-extinction target. More recently, the Colossal Foundation partnered with the University of Tasmania to develop vaccines and gene-editing approaches aimed at protecting Tasmanian devils from a contagious facial cancer.

Lamm has also said the company plans to spin out its artificial womb technology, which could eventually have applications in fertility treatment. Speaking to Rolling Stone in May, he said the technology could be ready next year.

Investor Interest In Deep Tech

The fundraising discussions come as investors increase spending on sectors such as biotechnology, longevity and other deep-tech fields.

Lamm has also said Colossal could eventually generate revenue from biodiversity credits if restored species are successfully reintroduced into their natural habitats, creating another potential commercial opportunity.

Breaking news